Barrett N, Eder G, Dorner F
Biomedical Research Center, Immuno AG, Orth/Donau, Austria.
Biotechnol Ther. 1991;2(1-2):91-106.
The human immunodeficiency virus (HIV-1) envelope glycoprotein gp160 was produced in large-scale microcarrier cultures of Vero cells, using a system involving coinfection with two recombinant vaccinia viruses. The immunogenicity of this material was studied in conjunction with a number of different adjuvant formulations, and chimpanzees were then immunized with gp160 in conjunction with Al(OH)3, Al(OH)3 and sodium deoxycholate, and a lipid-based adjuvant. The Al(OH)3-gp160 vaccine formulation elicited very poor immune responses in two chimpanzees, and these animals were further immunized with gp160 in conjunction with a lipid-based adjuvant. Immunization with the latter formulation lead to induction of high-titer neutralizing antibodies, and, following challenge with HIV-1, one chimpanzee demonstrated no evidence of virus infection over a period of 3 years. The second chimpanzee, which had previously been infected with non-A, non-B hepatitis, and two animals immunized with gp160 with Al(OH)3 and deoxycholate were not protected against challenge.
利用一种涉及两种重组痘苗病毒共感染的系统，在非洲绿猴肾细胞的大规模微载体培养物中生产了人类免疫缺陷病毒1型（HIV-1）包膜糖蛋白gp160。结合多种不同的佐剂配方研究了该物质的免疫原性，然后用gp160与氢氧化铝、氢氧化铝和脱氧胆酸钠以及一种脂质佐剂对黑猩猩进行免疫。氢氧化铝-gp160疫苗配方在两只黑猩猩中引发的免疫反应非常差，随后用gp160与脂质佐剂对这些动物进行了进一步免疫。用后一种配方免疫导致高滴度中和抗体的诱导，并且在用HIV-1攻击后，一只黑猩猩在3年的时间里没有显示出病毒感染的迹象。第二只黑猩猩此前感染了非甲非乙型肝炎，用gp160与氢氧化铝和脱氧胆酸钠免疫的另外两只动物在攻击后未受到保护。
